Introduction
Background of the study
Data and methodology
Study design and study area
Source of data
Target population
Variables of the study
Response variable
Explanatory variable
Variable | Category |
---|---|
Socio-demographic factors: | |
Age at diagnosis | 1 < = 40, 2 > 40 |
Education level Resident | 1 = primary,2 = secondary ,3 = degree and above 0 = urban, 1 = rural |
Marital status | 1 = single, 2 = married 3 = widowed, 4 = divorced |
Clinic-pathological factors | |
Pre-existing comorbidity | 1 = yes, 2 = no |
BMI at diagnosis | 1 = Normal, 2 = overweight |
Stage of cancer | 1 = I, 2 = II, 3 = III |
Histologic grade | 1 = grade I, 2 = grade II, 3 = grade III |
Surgical margin | 1 = free, 2 = involved |
Axillary Node status | 1 = negative ,2 = positive |
Number of Positive Lymph nodes involved | 0 = < 2 , 1 = >= 2 |
Tumor size | 0 = < 2 cm, 1 = 2.5–5 cm, 2 = > 5 cm |
Estrogen receptor | 1 = negative, 2 = positive ,3 = not determined |
Progesterone receptor | 1 = positive, 2 = negative |
Treatment-related factors | |
Baseline treatment | 0 = Surgery, 1 = Chemotherapy, 2 = Chemotherapy & Surgery |
Duration from date of diagnosis to surgery | 1 = < 30 days, 2 = >= 30 days |
Adjuvant chemotherapy use | 1 = yes, 2 = no |
Type of chemotherapy regimen | 1 = AC, 2 = Paclitaxel, 3 = Combination |
Hormone therapy use | 0 = yes, 1 = no |
Type of hormone used | 1 = Tamoxifen, 2 = Anastrozole |
Inclusion and exclusion criteria
Method of data collection
Methods of analysis
Result
Variable | Category | Status | ||||
---|---|---|---|---|---|---|
Survive | Death | |||||
Count | Percent | Count | Present | Total | ||
Ages at diagnosis | Less than 40 | 340 | 86.3% | 16 | 10.1% | 356(64.5%) |
more than or equal 40 | 54 | 13.7% | 142 | 89.9% | 196(35.5%) | |
Place of residence of patient | Urban | 337 | 85.5% | 135 | 85.4% | 472(85.5%) |
Rural | 57 | 14.5% | 23 | 14.6% | 80(14.5%) | |
Education level | Primary | 220 | 55.8% | 105 | 66.5% | 325(58.9%) |
Secondary | 113 | 28.7% | 35 | 22.2% | 148(26.8%) | |
Degree and above | 61 | 15.5% | 18 | 11.4% | 79(14.3%) | |
Marital status | Single | 125 | 31.7% | 28 | 17.7% | 153(27.7%) |
Married | 186 | 47.2% | 91 | 57.6% | 277(50.2%) | |
Widowed | 76 | 19.3% | 36 | 22.8% | 112(20.3%) | |
Divorced | 7 | 1.8% | 3 | 1.9% | 10(1.8%) |
Variable | Category | Status | ||||
---|---|---|---|---|---|---|
Survive | Death | |||||
Count | percent | Count | percent | Total | ||
Pre-existing comorbidity | No | 330 | 83.8% | 23 | 14.6% | 353(63.9%) |
Yes | 64 | 16.2% | 135 | 85.4% | 199(36.1%) | |
Stage of cancer | Stage I | 191 | 48.5% | 61 | 38.6% | 252(45.6%) |
Stage II | 139 | 35.3% | 77 | 48.7% | 216(39.2%) | |
Stage III | 64 | 16.2% | 20 | 12.7% | 84(15.2%) | |
Histologic grade | Grade I | 34 | 8.6% | 24 | 15.2% | 58(10.5%) |
Grade II | 161 | 40.9% | 69 | 43.7% | 230(41.7%) | |
Grade III | 199 | 50.5% | 65 | 41.1% | 264(47.8%) | |
Surgical margin | Free | 255 | 64.7% | 117 | 74.1% | 372(67.4%) |
Involved | 139 | 35.3% | 41 | 25.9% | 180(32.6%) | |
Axillary Node status | Negative | 301 | 76.4% | 117 | 74.1% | 418(75.7%) |
Positive | 93 | 23.6% | 41 | 25.9% | 134(24.3%) | |
BMI at diagnosis | Overweight | 145 | 36.8% | 156 | 98.7% | 301(54.5%) |
Normal | 249 | 63.2% | 2 | 1.3% | 251(45.5%) | |
Number of Positive Lymph nodes involved | <=2 | 93 | 23.6% | 41 | 25.9% | 134(24.3%) |
>=2 | 301 | 76.4% | 117 | 74.1% | 418(75.7%) | |
Tumor size | < 2 cm | 108 | 27.4% | 43 | 27.2% | 151(27.4%) |
2.5-5 cm | 59 | 15.0% | 36 | 22.8% | 95(17.2%) | |
>=5 cm | 227 | 57.6% | 79 | 50.0% | 306(55.4%) | |
Estrogen receptor | Negative | 163 | 41.4% | 83 | 52.5% | 246(44.6%) |
Positive | 161 | 40.9% | 54 | 34.2% | 215(38.9%) | |
Not Determine | 70 | 17.8% | 21 | 13.3% | 91(16.5) | |
Progesterone receptor | Positive | 255 | 64.7% | 68 | 43.0% | 323(58.5%) |
Negative | 139 | 35.3% | 90 | 57.0% | 229(41.5%) |
Variable | Category | Status | ||||
---|---|---|---|---|---|---|
Survive | Death | |||||
Count | percent | Count | Percent | Total | ||
Baseline treatment | Surgery | 128 | 32.5% | 65 | 41.1% | 193(35%) |
Chemotherapy | 164 | 41.6% | 59 | 37.3% | 223(40.4%) | |
Surgery and chemotherapy | 102 | 25.9% | 34 | 21.5% | 136(24.6%) | |
Duration from date of diagnosis to surgery | < 30 | 254 | 64.5% | 101 | 63.9% | 355(64.3%) |
>=30 | 140 | 35.5% | 57 | 36.1% | 197(35.7%) | |
Adjuvant chemotherapy use | Yes | 128 | 32.5% | 63 | 39.9% | 193(34.6%) |
No | 266 | 67.5% | 95 | 60.1% | 361(65.4%) | |
Type of chemotherapy regimen | AC | 150 | 38.1% | 77 | 48.7% | 227(41.1%) |
Paclitaxel | 75 | 19.0% | 26 | 16.5% | 101(18.2%) | |
Combination | 169 | 42.9% | 55 | 34.8% | 224(40.5%) | |
Hormone therapy use | Yes | 320 | 81.2% | 132 | 83.5% | 452(82%) |
No | 74 | 18.8% | 26 | 16.5% | 100(18%) | |
Type of hormone used | Tamoxifen | 181 | 45.9% | 23 | 14.6% | 204(37%) |
Anastro zole | 213 | 54.1% | 135 | 85.4% | 348(63%) |
Non-parametric survival analysis
Survival comparison of different groups of BM patients
Multivariate AFT analysis
Distribution | AIC | BIC | Log-likelihood |
---|---|---|---|
Exponential | 538.426 | 660.823 | -240.213 |
Weibull | 519.786 | 646.4037 | -229.893 |
Log logistic | 526.044 | 652.66 | -233.022 |
Log-normal | 525.4011 | 652.0188 | -232.701 |
Generalized gamma | 521.659 | 652.4973 | -229.8295 |
Gompertz | 528.7558 | 655.3735 | -234.378 |
Variable | Coefficient | Std. err. | z | P>|z| | ϕ | [95% conf. interval] | |
---|---|---|---|---|---|---|---|
Age in year | |||||||
>= 40 | 5.54 | 0.81 | 6.83 | 0.000* | 254.06 | 3.95 | 7.13 |
Education | |||||||
Secondary | -0.83 | 0.22 | -3.86 | 0.000* | 0.43 | -1.26 | -0.41 |
Degree and abo | -1.99 | 0.29 | -6.97 | 0.000* | 0.14 | -2.55 | -1.43 |
Residence | |||||||
Urban | -0.18 | 00.09 | -1.99 | 0.047* | 0.84 | -0.35 | -0.00 |
Marital status | |||||||
Married | 0.26 | 0.11 | 2.43 | 0.015* | 1.30 | 0.05 | 0.47 |
Widowed | -1.32 | 0.13 | -9.94 | 0.000* | 0.27 | -1.58 | -1.06 |
Divorced | 0.13 | 0.18 | 0.73 | 0.464 | 1.14 | -0.22 | 0.48 |
Pre-existing comorbidity | |||||||
Yes | 0.90 | 0.26 | 3.47 | 0.001* | 2.46 | 0.39 | 1.41 |
Axillary Node status | |||||||
Positive | -3.16 | 0.66 | -4.83 | 0.000* | 0.04 | -4.45 | -1.88 |
Estrogen receptor | |||||||
Positive | -1.01 | 0.20 | -5.01 | 0.000* | 0.36 | -1.41 | -0.62 |
Not determine | -0.09 | 0.27 | -0.35 | 0.729 | 0.91 | -0.62 | 0.43 |
Tumor size | |||||||
2–5 | -0.91 | 0.27 | -3.43 | 0.001* | 0.40 | -1.44 | -0.39 |
> 5 cm | − 0.9496681 | 0.2478244 | -3.83 | 0.000* | 0.39 | -1.44 | -0.46 |
Body Mass Index at diagnosis | |||||||
Overweight | 2.99 | 0.72 | 4.13 | 0.000* | 0.05 | -4.41 | -1.57 |
Progesterone receptor | |||||||
Negative | -0.95 | 0.26 | -3.66 | 0.000* | 0.39 | -1.46 | -0.44 |
Stage of cancer | |||||||
Stage II | -0.66 | 0.20 | -3.25 | 0.001* | 0.52 | -1.05 | -0.26 |
Stage III | -0.90 | 0.29 | -3.15 | 0.002* | 0.40 | -1.47 | -0.34 |
Histologic grade | |||||||
Grade II | 0.17 | 0. 0.21 | 0.81 | 0.419 | 1.19 | -0.25 0.60 | |
Grade III | 0.16 | 0.22 | 0.75 | 0.455 | 1.17 | -0.26 | 0.56 |
Number of Positive Lymph nodes involved | |||||||
>=2 | -0.80 | 0.16 | -0.51 | 0.611 | 0.45 | -0.40 | 0.23 |
Baseline treatment | |||||||
Chemotherapy | -0.20 | 0.21 | -0.93 | 0.351 | 0.82 | -0.61 | 0.22 |
Surgery and chem. | -0.64 | 0.25 | -2.61 | 0.009* | 0.53 | -1.12 | -0.16 |
Type of hormone used | |||||||
Anastrozole | -0.32 | 0.21 | -1.53 | 0.125 | 0.73 | -0.72 | 0.09 |
Constant | 4.95 | 0.49 | -2.97 | 0.000 | 140.55 | 3.96 | 5.89 |